Long-Term Exposure to Fine Particulate Matter (PM2.5) and Cardiovascular Disease Mortality among Renal Transplant Recipients







Abstract
Open Access
ISSN 2577-5820
© 2019 by the authors; CC BY 4.0 licence
OBM Transplantation , Volume 3 , Issue 4 (2019)
Pages: 114
Published: January 2020
(This book is a printed edition that was published in OBM Transplantation)
Cover story: Bronchiolitis Obliterans Syndrome (BOS) or Chronic Lung Allograft Dysfunction (CLAD) after Lung Transplantation, are dramatically common in their prevalence and detrimental effects on long term survival. Indeed data from International Society of Heart and Lung Transplantation report a median BOS-free survival of only 3.16 and 3.58 years after Single and Bilateral Lung Transplant while for 5-year survival, a sobering 55.8% and 66.2%, respectively. Therefore, novel innovative therapies which target the pathobiology of CLAD are critical. In our pilot study in OBM Transplantation, we have yet scratched the surface regarding the potential therapeutic effects of IL-6 receptor blockade and the complex detrimental interactions of IL-6 and TH-17 in contributing to CLAD, based on our original observations from rodent models. Herein we report an amelioration for the decrement in Slope for Forced Expiratory Volume (FEV)-1 sec in nine lung transplant recipients with CLAD who received combination immune modulation therapies that included TOCILIZUMAB, a humanized monoclonal antibody to the IL-6 receptor alpha (FEV-1 Slope PRE: -0.132+0.0148 versus POST: -0.012+0.049 L/month. To our knowledge, these represent the first human data after lung transplant and suggest prospective, multi-center, RCT which target the pathologic increase in cytokines / chemokines in CLAD would be appropriate for additional investigation for this devastating complication of clinical lung transplantation. View this paper.
Volume 3,Issue 4
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
Abstract
TOP